Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_2
1
20%
Ph not_applicable
1
20%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 2Efficacy & side effects
1(50.0%)
N/ANon-phased studies
1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Other(5)

Detailed Status

unknown5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 21 (50.0%)
N/A1 (50.0%)

Trials by Status

unknown5100%

Recent Activity

0 active trials
Showing 5 of 5
unknown

DNA CDO1 and CELF4 Methylation for Endometrial Cancer Screening

NCT05290922
unknown

Host DNA Methylation for Endometrial Cancer Screening

NCT05290415
unknown

DNA PAX1 and JAM3 Methylation for Cervical Cancer Screening

NCT05290428
unknownnot_applicable

Cell-free DNA Methylation for Endometrial Cancer

NCT04651738
unknownphase_2

Cell-free DNA Methylation for Epithelial Ovarian Cancer

NCT04651946

Clinical Trials (5)

Showing 5 of 5 trials
NCT05290922

DNA CDO1 and CELF4 Methylation for Endometrial Cancer Screening

Unknown
NCT05290415

Host DNA Methylation for Endometrial Cancer Screening

Unknown
NCT05290428

DNA PAX1 and JAM3 Methylation for Cervical Cancer Screening

Unknown
NCT04651738Not Applicable

Cell-free DNA Methylation for Endometrial Cancer

Unknown
NCT04651946Phase 2

Cell-free DNA Methylation for Epithelial Ovarian Cancer

Unknown

All 5 trials loaded

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
5